High-mobility group box 1 protein (HMGB1) neutralization ameliorates experimental autoimmune encephalomyelitis

• Published in: Journal of autoimmunity Vol. 43; pp. 32 - 43
• Main Authors: Robinson, Andrew P, Caldis, Matthew W, Harp, Christopher T, Goings, Gwendolyn E, Miller, Stephen D
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01.06.2013; Elsevier
• Subjects: Allergy and Immunology; Animals; Antibodies, Neutralizing - administration & dosage; Autoimmune disease; Biological and medical sciences; CD4-Positive T-Lymphocytes - immunology; CD4-Positive T-Lymphocytes - pathology; Central Nervous System - immunology; Central Nervous System - pathology; Cytokines - biosynthesis; EAE; Encephalomyelitis, Autoimmune, Experimental - immunology; Encephalomyelitis, Autoimmune, Experimental - prevention & control; Encephalomyelitis, Autoimmune, Experimental - therapy; Fundamental and applied biological sciences. Psychology; Fundamental immunology; HMGB1; HMGB1 Protein - antagonists & inhibitors; HMGB1 Protein - blood; HMGB1 Protein - immunology; Humans; Innate immunity; Lymphocyte Activation; Medical sciences; Mice; Mice, Inbred C57BL; Multiple Sclerosis - immunology; Multiple Sclerosis - therapy; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; Neuroimmunomodulation; Neuroinflammation; Neurology; Tolerance; Innate immunity; Autoimmune disease; CNS; HMGB1; experimental autoimmune encephalomyelitis; PLP; CSF; damage-associated molecular pattern; MBP; TLR; myelin oligodendrocyte glycoprotein; peripheral blood mononuclear cells; proteolipid protein; MOG; MS; multiple sclerosis; EAE; Tolerance; Neuroinflammation; myelin basic protein; RAGE; PBMCs; central nervous system; delayed-type hypersensitivity; high-mobility group box 1 protein; cerebrospinal fluid; DTH; toll-like receptor; DAMP; receptor for advanced glycation end-products; Autoimmunity; Immunopathology; Animal model; Nervous system diseases; Multiple sclerosis; HMGB1 Protein; Natural immunity; Experimental allergic encephalomyelitis; Inflammatory disease; Immunology; Central nervous system disease; Neutralization

Abstract Multiple sclerosis (MS) is an autoimmune, demyelinating disease and as such, the gold standard of treatment is to selectively suppress the pathogenic autoimmune response without compromising the entire arm of the adaptive immune response. One target of this strategy lying upstream of the pa...